New Orleans, LA -- A collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively. The findings are published online in MDPI Cancers, available here .

https://www.miragenews.com/lsu-health-proposes-novel-treatment-for-1062699/

#miragenews